AbbVie Inc.

🇺🇸New York Stock Exchange
Back to all articles
AbbVie Inc. stock analysis ABBV overview
Bullish +55

ABBV: Game-Changing Data on Venetoclax Unveiled!

📈 AbbVie unveiled nine-year follow-up data from the CLL14 trial showing venetoclax provides a median of ~8 years off treatment in first-line chronic lymphocytic leukemia.

💰 The board approved a ~5.8% quarterly dividend hike to $1.64 per share starting February 2025, maintaining a streak of annual increases since the 2013 spin-off.

💵 AbbVie generated $18.8 billion in operating cash flow in 2024, funding $11.0 billion in dividends and leaving over $7 billion in free cash flow.

📉 Total long-term debt stood at about $67 billion as of year-end 2024, with the company paying down a net $9.6 billion in 2024 to reduce leverage.

🏆 Moody's upgraded AbbVie's credit rating to A2 Stable in early 2026, citing improving post-Humira performance and strong free cash flow generation.

📊 Shares rallied approximately 25% over the past year as of early 2026, driven by optimism in new immunology and oncology products.

⚠️ Humira U.S. patent expired in January 2023, causing sales to plunge 41% in 2024 as the company transitions to newer therapies.

🔬 Skyrizi revenue jumped ~76% in 2022 with continued double-digit growth through 2024, helping offset declines in legacy immunology drugs.

⚖️ AbbVie carries over $70 billion in goodwill and intangible assets, taking a $3.5 billion impairment charge on certain assets in 2024.

📉 U.S. Medicare negotiations under the Inflation Reduction Act have targeted AbbVie's Imbruvica for future price controls.

Bullish Signals
  • Landmark nine-year data from the CLL14 trial confirms venetoclax offers a median of ~8 years off treatment, affirming its safety and efficacy in first-line chronic lymphocytic leukemia.
  • AbbVie increased its quarterly dividend by ~5.8% to $1.64 per share starting February 2025, extending a multi-year streak of consistent dividend growth.
  • The company generated $18.8 billion in operating cash flow in 2024, easily funding dividends and leaving over $7 billion in free cash flow for debt reduction or investments.
  • Moody's upgraded AbbVie's credit rating to A2 Stable with a stable outlook, reflecting improving post-Humira performance and robust annual free cash flow exceeding $10 billion after dividends.
  • AbbVie paid down a net $9.6 billion of debt in 2024 while maintaining investment-grade ratings (S&P affirmed A–), demonstrating active balance sheet management.
  • Shares returned about 25% over the past year as of early 2026, reflecting strong market confidence in the company's new immunology and oncology product pipeline.
  • Skyrizi revenue grew rapidly with a ~76% jump in 2022 and sustained double-digit growth through 2024, signaling successful replacement of legacy drug sales.
Risk Factors
  • AbbVie's GAAP P/E ratio exceeds 100 due to heavy non-cash amortization charges, making the stock appear richly valued on trailing earnings despite a more reasonable forward multiple.
  • The company carries a significant debt load of approximately $67 billion as of year-end 2024, which limits flexibility for future acquisitions or major R&D spending spikes.
  • AbbVie took a $3.5 billion impairment charge on certain intangible assets in 2024, reflecting disappointments in parts of its acquired portfolio and signaling potential underperformance.
  • Humira, Skyrizi, and Rinvoq together accounted for ~47% of total revenue in 2024, creating high product concentration risk if new drugs fail to fully replace Humira's peak sales.
Full Analysis
AbbVie (NYSE: ABBV) recently presented landmark nine-year follow-up data from the Phase 3 CLL14 trial at the European Hematology Association 2026 meeting. The results confirm that a one-year fixed-duration venetoclax combination therapy provides a median of approximately eight years off treatment before requiring further intervention. AbbVie's oncology leadership highlighted these findings as affirming the drug's enduring safety and efficacy, offering patients unprecedented time to their next treatment in first-line chronic lymphocytic leukemia. This clinical breakthrough reinforces AbbVie's post-Humira pipeline narrative, demonstrating its ability to innovate beyond its legacy immunology blockbusters. The company is strategically navigating the loss of exclusivity on Humira by leaning on new therapies like venetoclax, Skyrizi, and Rinvoq to drive future growth. Concurrently, AbbVie has increased its quarterly dividend to $1.64 per share starting February 2025, extending a multi-year streak of steady dividend growth despite the transition period. Financially, AbbVie generated $18.8 billion in operating cash flow in 2024, funding $11.0 billion in dividends while leaving over $7 billion in free cash flow. The company has actively deleveraged its balance sheet, paying down $9.6 billion of debt in 2024 and receiving a credit rating upgrade from Moody's to A2 Stable. While the stock trades at a premium valuation with a GAAP P/E over 100 due to non-cash charges, it offers a forward P/E of roughly 15–17x and a dividend yield near 2.8%.